May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

Update: 2024-09-30

Description

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.

Read the Commission:
https://www.thelancet.com/commissions/radiotherapy-theranostics?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Yannick Romero on the changing landscape of national cancer control plans

2025-01-0224:40

M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries

2024-12-0222:15

$Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma$

Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

2024-10-3015:07

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

2024-09-3017:21

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

2024-09-3040:45

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

2024-08-2713:22

Emmy Boerrigter on dose selection of novel anticancer drugs

2024-07-2911:41

Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations

2024-06-2436:56

Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment

2024-05-2824:08

James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean

2024-04-2935:05

Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials

2024-04-0811:22

Maria Kyrgiou on innovations in gynaecological cancers and global disparities

2024-03-0725:42

Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers

2024-02-2634:43

Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer

2024-01-2916:06

Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma

2024-01-0213:53

Neerja Bhatla on a new quadrivalent HPV vaccine

2023-11-2912:24

Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery

2023-11-0143:49

Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma

2023-10-3117:10

Wanda Cui on measuring ovarian toxicity

2023-10-0310:37

Ticiana Leal on Tumour Treating Fields

2023-09-0109:01

00:00

1.0x

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

#box-pro-ellipsis-173694139243146{-webkit-line-clamp:2;}May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

The Lancet Group

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics